Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Erin Quirk

Showing results (11-20 of 28) with videos related to

Pageof 3
Sort By:
Clinical Pharmacology in Drug Development|July 24, 2021
Safety, Pharmacokinetics, Pharmacodynamics, and Formulation of Liver-Distributed Farnesoid X-Receptor Agonist TERN-101 in Healthy VolunteersYujin Wang, Daria B Crittenden, Clarence Eng, et al.
Antimicrobial Agents and Chemotherapy|February 27, 2019
Resistance Analysis of Bictegravir-Emtricitabine-Tenofovir Alafenamide in HIV-1 Treatment-Naive Patients through 48 WeeksRima K Acosta, Madeleine Willkom, Ross Martin, et al.
Clinical and Vaccine Immunology : CVI|July 17, 2009
Safety and immunogenicity of the Merck adenovirus serotype 5 (MRKAd5) and MRKAd6 human immunodeficiency virus type 1 trigene vaccines alone and in combination in healthy adultsClayton Harro, Xiao Sun, Jon E Stek, et al.
The Lancet. HIV|February 22, 2017
Bictegravir versus dolutegravir, each with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection: a randomised, double-blind, phase 2 trialPaul E Sax, Edwin DeJesus, Gordon Crofoot, et al.
Nature Medicine|June 11, 2025
TERN-501 monotherapy and combination therapy with TERN-101 in metabolic dysfunction-associated steatohepatitis: the randomized phase 2a DUET trialMazen Noureddin, Naim Alkhouri, Eric J Lawitz, et al.
The Lancet. HIV|June 22, 2018
Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from dolutegravir plus abacavir and lamivudine in virologically suppressed adults with HIV-1: 48 week results of a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trialJean-Michel Molina, Douglas Ward, Indira Brar, et al.
AIDS (London, England)|February 10, 2018
Repeat testing of low-level HIV-1 RNA: assay performance and implementation in clinical trialsKirsten White, Will Garner, Lilian Wei, et al.
The Lancet. HIV|October 22, 2016
Safety, efficacy, and pharmacokinetics of a single-tablet regimen containing elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide in treatment-naive, HIV-infected adolescents: a single-arm, open-label trialAditya H Gaur, Hilda Kizito, Wasana Prasitsueubsai, et al.
Lancet (London, England)|July 4, 2012
Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeksPaul E Sax, Edwin DeJesus, Anthony Mills, et al.
Lancet (London, England)|September 5, 2017
Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380-1490): a randomised, double-blind, multicentre, phase 3, non-inferiority trialPaul E Sax, Anton Pozniak, M Luisa Montes, et al.
Pageof 3

Showing results (11-20 of 28) with videos related to

Sort By:
Pageof 3
Clinical Pharmacology in Drug Development|July 24, 2021
Safety, Pharmacokinetics, Pharmacodynamics, and Formulation of Liver-Distributed Farnesoid X-Receptor Agonist TERN-101 in Healthy VolunteersYujin Wang, Daria B Crittenden, Clarence Eng, et al.
Antimicrobial Agents and Chemotherapy|February 27, 2019
Resistance Analysis of Bictegravir-Emtricitabine-Tenofovir Alafenamide in HIV-1 Treatment-Naive Patients through 48 WeeksRima K Acosta, Madeleine Willkom, Ross Martin, et al.
Clinical and Vaccine Immunology : CVI|July 17, 2009
Safety and immunogenicity of the Merck adenovirus serotype 5 (MRKAd5) and MRKAd6 human immunodeficiency virus type 1 trigene vaccines alone and in combination in healthy adultsClayton Harro, Xiao Sun, Jon E Stek, et al.
The Lancet. HIV|February 22, 2017
Bictegravir versus dolutegravir, each with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection: a randomised, double-blind, phase 2 trialPaul E Sax, Edwin DeJesus, Gordon Crofoot, et al.
Nature Medicine|June 11, 2025
TERN-501 monotherapy and combination therapy with TERN-101 in metabolic dysfunction-associated steatohepatitis: the randomized phase 2a DUET trialMazen Noureddin, Naim Alkhouri, Eric J Lawitz, et al.
The Lancet. HIV|June 22, 2018
Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from dolutegravir plus abacavir and lamivudine in virologically suppressed adults with HIV-1: 48 week results of a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trialJean-Michel Molina, Douglas Ward, Indira Brar, et al.
AIDS (London, England)|February 10, 2018
Repeat testing of low-level HIV-1 RNA: assay performance and implementation in clinical trialsKirsten White, Will Garner, Lilian Wei, et al.
The Lancet. HIV|October 22, 2016
Safety, efficacy, and pharmacokinetics of a single-tablet regimen containing elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide in treatment-naive, HIV-infected adolescents: a single-arm, open-label trialAditya H Gaur, Hilda Kizito, Wasana Prasitsueubsai, et al.
Lancet (London, England)|July 4, 2012
Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeksPaul E Sax, Edwin DeJesus, Anthony Mills, et al.
Lancet (London, England)|September 5, 2017
Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380-1490): a randomised, double-blind, multicentre, phase 3, non-inferiority trialPaul E Sax, Anton Pozniak, M Luisa Montes, et al.
Pageof 3